Edgewise Therapeutics (EWTX) Cash from Financing Activities (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Cash from Financing Activities data on file, last reported at $12.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 447.59% year-over-year to $12.2 million; the trailing twelve-month figure through Mar 2026 stood at $206.0 million (up 1880.56% YoY), and the FY2025 full-year result was $196.1 million, down 21.33% from the prior year.
• Cash from Financing Activities grew to $12.2 million in Q1 2026, from $4.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $241.1 million in Q1 2024 to a low of -$303000.0 in Q4 2022.
• A 5-year average of $37.7 million and a median of $2.2 million in 2025 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 203.41% in 2022 and jumped 1147866.67% in 2024, its largest moves.
• Tracing EWTX's Cash from Financing Activities over 5 years: stood at -$303000.0 in 2022, then surged by 17587.46% to $53.0 million in 2023, then tumbled by 94.54% to $2.9 million in 2024, then surged by 37.31% to $4.0 million in 2025, then surged by 206.24% to $12.2 million in 2026.
• Business Quant data shows EWTX's Cash from Financing Activities at $12.2 million in Q1 2026, $4.0 million in Q4 2025, and $1.7 million in Q3 2025.